.png){kind=icon}
.png){kind=icon}
Return
A comprehensive engineering strategy improves potency and manufacturability of a near pan-neutralizing antibody against HIV
.png){kind=icon}
OA
AI
DOI：10.1016/j.str.2025.04.016.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
• Engineered bnAb N49P9.6-FR-LS shows best-in-class breadth, potency, and half-life • N49P9.6-FR-LS also combines well with bNAbs of other classes • Final variant eN49P9 is optimized for clinical-grade cGMP manufacturing • Enhanced bnAbs demonstrate strong antiviral potential and translational promise
Keywords:
HIV
monoclonal antibody
bnAb
neutralization
elite neutralizer
HIV cure
CD4 binding site
combination therapies
engineering
ADCC
Journal
IF:
4.3
Papers:
366
Citations:
1.4W
Organization
I
N
View more organizations